AstraZeneca’s hopes of positioning its PD-L1 inhibitor Imfinzi as a post-surgery therapy for people with earlier-stage lung cancer have taken a knock, although it performed well in a bladder ...

Imfinzi, either as a monotherapy or in combination with chemotherapy, is presently approved for stage III non-small cell lung cancer, extensive-stage small cell lung cancer, locally advanced or ...

Cancer researchers discovered how exercise really can be like a drug for colon cancer, and AstraZeneca's immunotherapy drug ...

AstraZeneca's PD-L1 inhibitor Imfinzi has become the immunotherapy to be approved in the US for limited-stage small cell lung cancer (LS-SCLC), a particularly challenging form of the disease.

The FDA raised the perioperative issue when discussing Imfinzi in early-stage non-small cell lung cancer. In that case, chemotherapy was only used before surgery, and AZ’s new regimen is adding ...

Limited-stage Small Cell Lung Cancer In patients with limited-stage SCLC in the ADRIATIC study receiving IMFINZI (n=262), the most common adverse reactions occurring in ≥20% of patients ...

AstraZeneca scores FDA nod for Imfinzi as first immunotherapy for limited-stage small cell lung cancer Amgen currently has three phase 3 trials running or being planned for Imdelltra in first-line ...

Imfinzi is an immunotherapy that is already approved in the EU to treat certain cases of lung cancer, biliary tract cancer, endometrial cancer and hepatocellular carcinoma. If approved for this latest ...

Ovarian cancer remains a significant global health challenge, often diagnosed at an advanced stage due to non-specific ...

The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small ...